Latest news with #artificialintelligence
Yahoo
10 hours ago
- Business
- Yahoo
What grads need to know as AI transforms the job market
Recent graduates are facing a tougher job market, and many are being forced to rethink how their skills align with a world increasingly shaped by artificial intelligence (AI). Sinan Aral, director of the MIT Initiative on the Digital Economy, joins Market Domination Overtime to explain how students and employers can adapt to the changing landscape. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.
Yahoo
18 hours ago
- Business
- Yahoo
Meta (META) AI Reaches 1 Billion Users, Eyes Paid Features and Subscriptions
We recently published a list of . In this article, we are going to take a look at where Meta Platforms, Inc. (NASDAQ:META) stands against other AI stocks on Wall Street's radar. Meta Platforms, Inc. (NASDAQ:META) is a global technology company. On May 28, CNBC reported that Meta Platforms, Inc. (NASDAQ:META)'s artificial intelligence assistant, Meta AI, has one billion monthly active users across the company's family of apps. CEO Mark Zuckerberg disclosed the news at the company's annual shareholders meeting, stating how the 'focus for this year is deepening the experience and making Meta AI the leading personal AI with an emphasis on personalization, voice conversations, and entertainment.' CNBC further remarked how this milestone follows Meta's April rollout of its stand-alone app for the tool. Zuckerberg wants the AI tool to keep growing before a business can be built around it. As the Meta AI assistant improves over time, 'there will be opportunities to either insert paid recommendations' or offer 'a subscription service so that people can pay to use more compute.' Photo by Timothy Hales Bennett on Unsplash 'It may seem kind of funny that a billion monthly actives doesn't seem like it's at scale for us, but that's where we're at.' Overall, META ranks 1st on our list of AI stocks on Wall Street's radar. While we acknowledge the potential of META as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than META and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Geeky Gadgets
19 hours ago
- Business
- Geeky Gadgets
Inside OpenAI's $500 Billion Stargate AI Megafactory with Sam Altman
What does it take to build the future of artificial intelligence? Imagine a sprawling 1,200-acre facility in Abilene, Texas, humming with the power of 400,000 GPUs, each working tirelessly to train the next generation of AI models. This is Stargate, OpenAI's audacious $500 billion project, a megafactory designed to meet the insatiable computational demands of artificial general intelligence (AGI). Backed by tech giants like Oracle and SoftBank, Stargate is more than just a data center—it's a bold statement in the global race to dominate AI innovation. But as the world marvels at its scale and ambition, questions loom: Can such a colossal endeavor balance technological progress with environmental and economic responsibility? Bloomberg steps inside a Stargate AI Megafactory to uncover its new infrastructure, its potential to transform industries, and the controversies it stirs. From its innovative cooling systems aimed at reducing resource strain to its role in reshaping Abilene's economy, Stargate offers a microcosm of the promises and perils of large-scale AI development. Along the way, you'll discover how OpenAI is positioning itself against rivals like Google and Microsoft, and why this project has become a flashpoint in the global AI arms race. As we peel back the layers of this megafactory, one question persists: Will Stargate be remembered as a triumph of human ingenuity or a cautionary tale of unchecked ambition? OpenAI's Stargate Overview What is Stargate? Stargate is a new initiative designed to meet the growing needs of AI infrastructure. Spanning an impressive 1,200 acres in Abilene, Texas, the project's first phase will feature eight colossal buildings equipped with 400,000 GPUs. These GPUs, primarily sourced from Nvidia, will serve as the foundation for training and deploying advanced AI models, including those aimed at achieving AGI—a milestone where AI systems can reason, learn, and solve problems with human-like proficiency. This ambitious project places OpenAI in direct competition with major technology companies like Microsoft, Google, Meta, and Amazon, all of whom are striving to lead the AI revolution. The scale of Stargate underscores the increasing reliance on computational power as AI becomes integral to industries ranging from healthcare to finance. By investing in such a massive infrastructure, OpenAI is positioning itself at the forefront of AI innovation, but it also faces scrutiny over the sustainability and efficiency of this approach. Competitors like DeepSeek are exploring alternative methods to achieve similar results with more efficient AI models, challenging the necessity of projects on Stargate's scale. Economic Impact on Abilene The Stargate project is poised to bring significant economic changes to Abilene, Texas. Local authorities have offered substantial tax incentives, including an 85% property tax abatement, to attract this massive investment. These incentives are expected to stimulate economic activity, create jobs, and potentially transform the region into a hub for technological innovation. However, the exact number of permanent jobs the project will generate remains uncertain, raising questions about the long-term benefits for the local community. For residents, Stargate represents a mix of opportunities and challenges. On one hand, the project could drive economic growth, increase property values, and attract ancillary businesses to the area. On the other hand, concerns about environmental costs, equitable distribution of benefits, and the potential strain on local resources have sparked debates. The project's success in fostering sustainable economic development will depend on how these trade-offs are managed. OpenAI Stargate Megafactory Tour with Sam Altman Watch this video on YouTube. Here is a selection of other guides from our extensive library of content you may find of interest on AI infrastructure. Environmental Challenges and Sustainability AI data centers like Stargate are notorious for their high resource consumption, particularly in terms of energy and water. To address these concerns, Stargate plans to implement a closed-loop water cooling system designed to minimize water usage while maintaining optimal GPU performance. This system reflects an effort to mitigate the environmental impact of the project, but it does not eliminate broader concerns about the sustainability of large-scale AI infrastructure. The energy demands of Stargate are another critical issue. While efforts are being made to incorporate renewable energy sources, much of the power required for such facilities still comes from fossil fuels. This reliance raises questions about the environmental footprint of AI growth, especially as global climate goals become increasingly urgent. The project highlights the tension between technological advancement and environmental responsibility, emphasizing the need for innovative solutions to balance these priorities. Global Competition and Geopolitical Implications Stargate is not just a technological endeavor; it is also a strategic move in the global race to dominate AI infrastructure. Countries like China are making significant investments in similar projects, intensifying competition and raising the stakes for technological leadership. This race is further complicated by supply chain dependencies on critical materials and semiconductors, many of which are sourced from regions like Taiwan and China. To address these challenges, the United States has introduced initiatives such as the CHIPS Act, aimed at boosting domestic semiconductor manufacturing and reducing reliance on foreign suppliers. These measures are designed to secure the supply chain while fostering collaboration with allied nations. Stargate, as part of this broader strategy, underscores the geopolitical dimensions of AI development and the importance of maintaining a competitive edge in this rapidly evolving field. Risks, Challenges, and Future Prospects The construction and operation of a project as vast as Stargate come with inherent risks and challenges. OpenAI has already reported significant financial losses, raising concerns about the long-term profitability and sustainability of such large-scale investments. Additionally, the rapid pace of AI development brings ethical dilemmas, including the potential for job displacement, misuse of advanced AI technologies, and the societal implications of AGI. Despite these challenges, Stargate holds the potential to reshape industries, accelerate scientific discovery, and create entirely new categories of employment. Comparisons have been drawn to fantastic infrastructure projects like the interstate highway system, which transformed economies and societies. Similarly, Stargate could drive global economic transformation, provided its benefits are distributed equitably and its risks are effectively managed. The project also raises important questions about regulation and governance. As AI continues to evolve, making sure that its development aligns with societal values and ethical standards will be crucial. Stargate's success will depend not only on its technological achievements but also on its ability to address these broader concerns. The Significance of Stargate in the AI Landscape Stargate represents a pivotal moment in the evolution of AI infrastructure. It embodies the intersection of technological ambition, economic development, and environmental sustainability, offering a glimpse into the future of innovation. As the global race for AI supremacy intensifies, projects like Stargate will play a critical role in shaping the trajectory of technology and its impact on society. Whether Stargate achieves its ambitious goals or becomes a cautionary tale of overreach remains to be seen. However, its significance in the AI landscape is undeniable. By addressing the challenges of scalability, sustainability, and ethical responsibility, Stargate has the potential to set a new standard for AI infrastructure and redefine what is possible in the era of artificial intelligence. Media Credit: Bloomberg Originals Filed Under: AI, Top News Latest Geeky Gadgets Deals Disclosure: Some of our articles include affiliate links. If you buy something through one of these links, Geeky Gadgets may earn an affiliate commission. Learn about our Disclosure Policy.
Fast Company
a day ago
- Health
- Fast Company
The lab of the future: An artificial superintelligence for biology
The lab as we know it today is being transformed by how we think about medical research and drug discovery, as well as the intersection of artificial intelligence and biotechnology. As someone who has transitioned from a doctor to a tech CEO, I've witnessed firsthand how our mindset around medicine and innovation needs to evolve to keep pace with the accelerating changes in technology. In my journey, one of the most important lessons I've learned is: You can be too smart for your own good. It may sound counterintuitive, but when building a company or investing in new technologies, the smartest people often fall into the trap of overcomplicating things. A brilliant idea isn't always enough. You need the right people who can think creatively, take risks, and make it happen in the real world. For me, the mindset shift from doctor to CEO was about understanding that it's not just about medical knowledge; it's about building the right ecosystem to nurture that knowledge and turn it into real and transformative change. I believe that a crucial part of that ecosystem for my company, Owkin, is a new form of intelligence: a biological artificial superintelligence (BASI) to complement the ingenious human minds working with us. Next generation AI tools, like K Navigator, Owkin's agentic co-pilot for researchers, and K Pro for pharma, which is in the pipeline, will allow us to understand the full complexity of biology that has been beyond human understanding so far. This forms the backbone of Owkin's mission: We are creating the next-generation pharma focused on discovering cures and significantly enhancing pipeline value by developing a new intelligence system capable of decoding biological truths at scale. AI can fill the innovation gap left by pharma As the pharmaceutical industry increasingly focuses on a handful of blockbuster drugs, it's leaving behind many areas of medicine that are crucial for the future of healthcare. Too many diseases remain uncured as traditional pharma struggles to navigate the complexity of biology to augment care with efficient new molecules and diagnostics. From rare diseases to precision oncology, there's an innovation gap that AI is perfectly positioned to fill. AI can identify previously overlooked opportunities and streamline the development of treatments that are highly personalized and targeted. Unlike traditional pharmaceutical companies that are heavily reliant on large-scale, high-risk projects, AI companies can operate in a more agile, data-driven way. We can make smaller, more informed bets, leveraging machine learning and vast datasets to uncover insights that were once out of reach. This shift enables faster and more efficient drug discovery, with the added benefit of offering solutions for diseases that may not have attracted the attention of big pharma. Cell lines alone aren't going to work Most traditional biological research has been based on cell lines—cells removed from the human body and grown in petri dishes. But as we look to the future, there's a growing realization that cell lines, and other traditional research methods, are becoming outdated. While once a staple in biomedical research, they do not accurately replicate the complexity of human biology, and they fail to capture the diversity and variability that exists in real patients. AI-driven models are capable of moving beyond the limitations of cell lines by integrating data both from research done in cells and tissues removed from the body (in vitro) and from research done in living animals (in vivo). This validation approach, which incorporates multiple data types and sources, allows us to create more reliable and predictive models of human diseases. Science is advancing, and so is regulation. The FDA's recent announcement of plans to phase out animal testing in favor of 'more effective, human-relevant methods' means that we are entering an era where therapies can be tested on human tissue models from the very start. In collaboration with leading academic centers, Owkin has developed a patient-derived, lab-grown organoid (a mini version of a human organ), a breakthrough that brings us closer to faster, more accurate, and humane drug discovery. The combination of clinical data, genomic insights, and AI not only accelerates the development of new treatments but also increases their chances of success in clinical trials. The lab of the future The lab of the future will be one where AI is at the center, guiding discovery, improving precision, and increasing efficiency. Validation using real-world data will allow us to make better decisions and achieve higher rates of success. The traditional research process is being upended by these new technologies, and that's a good thing. The future of medicine will not just rely on human expertise, but on the power of AI and data to transform how we understand and treat disease. AI will deliver transformative therapies at an exponential scale, addressing the complexities of biology that traditional pharmaceutical approaches often cannot solve. Labs will become automated and serve as the ultimate playground for scientists, driving the future of drug discovery by harnessing the full potential of advanced AI systems. In these dynamic labs, organoids and agents will come together to work in synergy, allowing scientists to model and simulate human biology with greater accuracy. AI-driven technology will decipher biological patterns to identify the patients most likely to respond to specific treatments, significantly improving the chances of success in clinical trials and beyond. Seamlessly integrating these cutting-edge tools into the lab environment will transform the way we approach drug discovery, targeting diseases with a level of precision that was previously unimaginable. By pioneering the use of data, biology, and AI to decode the fundamental mechanics of disease and advance medical science, it will be possible to establish a foundation for the future of a 'positive singularity' in medicine. Through this innovative ecosystem, AI can revolutionize medicine. The time to innovate is now, and the possibilities are endless.
Bloomberg
a day ago
- Business
- Bloomberg
Builder.ai Faked Business With Indian Firm VerSe to Inflate Sales, Sources Say
the artificial intelligence startup that recently announced plans to declare bankruptcy, faked business with the Indian social-media startup VerSe Innovation for years to falsely inflate its sales, according to documents reviewed by Bloomberg and people with direct knowledge of the practice. The two companies routinely billed one another for roughly the same amounts between 2021 and 2024, documents reviewed by Bloomberg show, as part of an alleged practice known as "round-tripping" that the people said used to inflate revenue figures it presented to investors. In many cases, products and services weren't actually provided to either company for these payments, said the people, who asked not to be identified discussing confidential information. Umang Bedi, a VerSe co-founder, said it was 'absolutely baseless and false' that his company would have recorded expenses or billed services that it didn't receive or provide. 'We're not the kind of company that is in the business of inflating revenues,' he said in an interview.
